Hamilton Samina, Bernstein Aaron B, Blakey Graham, Fagan Vivien, Farrow Tracy, Jordan Debbie, Seiler Walther, Shannon Anna, Gertel Art
European Medical Writers Association, Chester House, 68 Chestergate, Macclesfield, Cheshire SK11 6DY UK.
Sam Hamilton Medical Writing Services Limited, Newcastle Upon Tyne, UK.
Res Integr Peer Rev. 2016 May 3;1:4. doi: 10.1186/s41073-016-0009-4. eCollection 2016.
Interventional clinical studies conducted in the regulated drug research environment are reported using International Council for Harmonisation (ICH) regulatory guidance documents: ICH E3 on the structure and content of clinical study reports (CSRs) published in 1995 and ICH E3 supplementary Questions & Answers (Q & A) published in 2012.Since the ICH guidance documents were published, there has been heightened awareness of the importance of disclosure of clinical study results. The use of the CSR as a key source document to fulfil emerging obligations has resulted in a re-examination of how ICH guidelines are applied in CSR preparation. The dynamic regulatory and modern drug development environments create emerging reporting challenges.
Regulatory medical writing and statistical professionals developed Clarity and Openness in Reporting: E3-based (CORE) Reference over a 2-year period. Stakeholders contributing expertise included a global industry association, regulatory agency, patient advocate, academic and Principal Investigator representatives.
CORE Reference should help authors navigate relevant guidelines as they create CSR content relevant for today's studies. It offers practical suggestions for developing CSRs that will require minimum redaction and modification prior to public disclosure.CORE Reference comprises a Preface, followed by the actual resource. The Preface clarifies intended use and underlying principles that inform resource utility. The Preface lists references contributing to development of the resource, which broadly fall into 'regulatory' and 'public disclosure' categories. The resource includes ICH E3 guidance text, ICH E3 Q & A 2012-derived guidance text and CORE Reference text, distinguished from one another through the use of shading. Rationale comments are used throughout for clarification purposes.A separate mapping tool comparing ICH E3 sectional structure and CORE Reference sectional structure is also provided.Together, CORE Reference and the mapping tool constitute the user manual.
This publication is intended to enhance the use, understanding and dissemination of CORE Reference.The CORE Reference user manual and the associated website (http://www.core-reference.org) should improve the reporting of interventional clinical studies.Periodic updates of CORE Reference are planned to maintain its relevance.
CORE Reference was registered with http://www.equator-network.org on 23 March 2015.
在规范的药物研究环境中开展的干预性临床研究,需依据国际协调会议(ICH)的监管指南文件进行报告:1995年发布的关于临床研究报告(CSR)结构和内容的ICH E3,以及2012年发布的ICH E3补充问答(Q&A)。自ICH指南文件发布以来,人们对临床研究结果披露的重要性有了更高的认识。将CSR用作履行新出现义务的关键源文件,促使人们重新审视ICH指南在CSR编制中的应用方式。动态的监管和现代药物研发环境带来了新出现的报告挑战。
监管医学写作和统计专业人员在两年时间里制定了《报告中的清晰与开放:基于E3》(CORE)参考文件。贡献专业知识的利益相关者包括全球行业协会、监管机构、患者权益倡导者、学术代表和主要研究者代表。
CORE参考文件应有助于作者在创建与当今研究相关的CSR内容时遵循相关指南。它为编写CSR提供了实用建议,这些CSR在公开披露前只需进行最少的编辑和修改。CORE参考文件包括前言,其后是实际资源。前言阐明了预期用途和指导资源效用的基本原则。前言列出了对该资源开发有贡献的参考文献,这些文献大致分为“监管”和“公开披露”两类。该资源包括ICH E3指南文本、源自2012年ICH E3问答的指南文本和CORE参考文件文本,通过使用阴影加以区分。通篇使用了理由注释以作说明。还提供了一个单独的映射工具,用于比较ICH E3章节结构和CORE参考文件章节结构。CORE参考文件和映射工具共同构成用户手册。
本出版物旨在加强CORE参考文件的使用、理解和传播。CORE参考文件用户手册及相关网站(http://www.core-reference.org)应能改善干预性临床研究的报告。计划对CORE参考文件进行定期更新以保持其相关性。
CORE参考文件于2015年3月23日在http://www.equator-network.org注册。